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Background: Eighty per cent of adolescents living with perinatally and behaviourally 
acquired HIV live in sub-Saharan Africa (SSA), a continent with marked economic 
inequality. Extending our previous global description of adolescents living with perinatally 
acquired HIV (APH), this analysis aimed to describe APH outcomes in SSA by country 
income group (CIG). 
Methods: Through the CIPHER cohort collaboration, individual retrospective data from 12 
cohort networks across 5 continents were pooled; 7 networks representing SSA were included 
here. APH included were HIV-infected children with entry into care at age <10 years (proxy 
for perinatally acquired HIV) and follow-up at age >10 years. CIG was classified according 
to World Bank Classification at median year of first visit by country. Cumulative incidence 
functions were calculated by competing risk analysis for mortality, transfer-out and loss-to-
follow-up. 
Results: A total of 30,296 APH were included; 75.7% resident in low-income countries 
(LIC), 4.6% in lower-middle-income countries (LMIC) and 19.8% in upper-middle-income 
countries (UMIC); 64% of APH were born ≥2000. Median (interquartile range [IQR]) age at 
antiretroviral therapy (ART) start (8 [6;9] years) and at last follow-up (12 [11;14] years) was 
equivalent across CIG. About 26,018 (85.9%) ever started ART and 3352 (12.5%) started at 
age >10 years, both significantly different between CIG (p < 0.001) (Table 1). Individual 
CD4 count improved between ART start and last visit in all CIG (p < 0.001). Half of APH 
had height-for-age z-score (HAZ) <−2 at ART start that improved by last visit in LIC (p < 
0.001) and UMIC (p < 0.001) but not in LMIC (p = 0.18). Mortality between age 10 and 15 
years was lowest in UMIC; however, loss-to-follow-up was highest in UMIC. 
MOAB0203 Table 1. APH characteristics by CIG (N = 30,296). 
 Conclusions: Despite starting ART late, improvements in height and CD4 count were 
observed in most APH surviving to adolescence. Mortality rates are likely underestimated. 
However, results highlight inequalities in mortality and access to ART according to CIG in 
SSA. 
 
